Production (Stage)
Bolt Biotherapeutics, Inc.
BOLT
$5.77
-$0.33-5.41%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.22M | 0.00 | 1.14M | 1.28M | 5.27M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.22M | 0.00 | 1.14M | 1.28M | 5.27M |
| Cost of Revenue | 9.19M | 11.72M | 13.79M | 15.43M | 15.55M |
| Gross Profit | -7.97M | -11.72M | -12.64M | -14.16M | -10.28M |
| SG&A Expenses | 3.83M | 3.95M | 3.80M | 4.87M | 5.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.34M | 15.67M | 17.58M | 20.31M | 22.37M |
| Operating Income | -12.12M | -15.67M | -16.44M | -19.03M | -17.09M |
| Income Before Tax | -11.04M | -15.94M | -15.18M | -21.20M | -10.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.04M | -15.94M | -15.18M | -21.20M | -10.81M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.04M | -15.94M | -15.18M | -21.20M | -10.81M |
| EBIT | -12.12M | -15.67M | -16.44M | -19.03M | -17.09M |
| EBITDA | -11.72M | -15.24M | -16.00M | -18.58M | -16.63M |
| EPS Basic | -5.76 | -8.32 | -7.94 | -11.12 | -5.68 |
| Normalized Basic EPS | -3.60 | -4.80 | -4.96 | -5.78 | -5.08 |
| EPS Diluted | -5.76 | -8.32 | -7.94 | -11.12 | -5.68 |
| Normalized Diluted EPS | -3.60 | -4.80 | -4.96 | -5.78 | -5.08 |
| Average Basic Shares Outstanding | 1.92M | 1.91M | 1.91M | 1.91M | 1.90M |
| Average Diluted Shares Outstanding | 1.92M | 1.91M | 1.91M | 1.91M | 1.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |